Digital RESI June 2020: Innovation Challenge Finalists Announced!

21 May

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day Digital RESI June Conference is coming up in less than 3 weeks, and we are very excited to announce our Innovation Challenge finalists. With a diverse representation across therapeutics, medical devices, diagnostics, and digital health, these companies were selected on the basis of innovative technology, strong management team, clear pathway to commercialization, and other positive factors that demonstrated high growth potential.

This will be our second time organizing a “digital” Innovation Challenge, and each company will have a dedicated webpage as part of our virtual conference agenda. These pages will feature a virtual poster and any non-confidential materials they would like to share with the conference attendees. Attendees will be able to vote for their favorite technologies during the 3-day span, and the Top 3 winners will be announced at the end of the conference and featured on our weekly LSN newsletter of 36,000 subscribers on Thursday.

We would like to thank all applicants for their interest in the upcoming RESI and our Innovation Challenge. Congratulations to the selected finalists – please see their clickable logos below!

Therapeutics

Medical Devices

Diagnostics

Digital Health

Get Ready for Successful Partnering Meetings

21 May

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

Partnering for Digital RESI June is up and running, and you have your company and personal profiles refined, updated and uploaded to the platform. You are diligently identifying the investors who are the best fit for your technology and stage of development and have begun to request a lot of meetings with the 400 investors and strategic partners who will be participating. You will soon start to get the first confirmations of meetings and you will be following up and sending out new requests over the next 3 weeks to get as many meetings booked as possible for June 8th-10th.

Now you need to start preparing for those important meetings.  Begin to prepare your meetings early to be as ready as possible when RESI begins. Your goal is to make enough of an impression in that 30-minute meeting on each of your potential investors that you get a commitment to have a next meeting. Here are some tips on how to make the most out of those crucial 30 minutes:

1. Research the Investor Firm

Try to understand the investment firm with whom you are meeting. Typically, there is a lot of information on the firm’s website about their mission and philosophy, as well as their portfolio of companies in which they have invested. This information is key to understanding how your company might fit in. Take notes of the reasons you see a potential to work together that you can bring up during the meeting.

2. Research the person you are meeting with

You will know in advance who you are meeting with from each of the investor firms. Be sure to learn all you can about the person you will be meeting with. One important thing to discover is the background and experience of your meeting counterpart. If you see that they happen to have a deep background in your particular area of technology, you might focus your pitch differently than if they have a background in finance and business.

3. Prepare your elevator pitch

For a 30-minute meeting, it is crucial to get the investor’s attention and interest in a concise, clear pitch that highlights all of the key elements of your company, without going into deep and lengthy technical descriptions that will eat up your time. Focus on what is important and differentiates your technology or team. Let the conversation flow naturally. Engaging the investor in a discussion rather than running through your slides will often help retain investor interest.

4. Have back-up slides on hand

That doesn’t mean you are not prepared to go into more detail if you are asked a specific question. Have your slides prepared that you can easily access in case you need to explain your asset’s mechanism of action in more detail or your data achieved to date that you may have summarized in your initial pitch. You can never have too many backup slides to address questions that might come up during your meeting.

5. Bring a second attendee to meetings

You will be very focused on making your pitch and answering any questions that come up, so you likely will not be taking notes during the meeting. If you are having back-to-back meetings, it will be extremely challenging to remember all of the comments and questions from investors during each of your meetings, but that information is really important for your follow up. Having a colleague on hand to take good notes at the meetings is a really good way to be sure you don’t miss anything.

6. Prepare a binder with your notes for each meeting

You will hopefully be needing your laptop for multiple meetings during RESI, some of them back-to-back, so I highly recommend having a paper back-up of your pre-meeting notes on each of your meetings that you can quickly reference between meetings. A binder with your pre-prepared notes and space to take notes during the meeting will be very useful.

7. Have questions prepared in advance

Most of your meeting with a new potential investor will be about presenting your company and yourself, and answering questions from your investor counterpart, but you shouldn’t miss out on the opportunity to ask questions that you may have from your pre-meeting research. Questions can be about what role the investor will play in your company if they decide to make an investment—such as, do they take a seat on the Board—or if they typically want to be the lead investor or part of a syndicate. Another thing that is always good to know is how any investor can add value to your company if they invest in you; what experience, expertise or connections do they have in your field that can help you in the future?

Best of luck to you all at Digital RESI June. It is such an exciting opportunity for you to make meaningful connections that will drive your success.

Digital RESI June Welcomes BioHealth Capital Region as a Gold Sponsor

21 May

By Bryanna Allison, Business Development Manager, LSN

The action item today is keeping up your business momentum in these challenging days. LSN has seen a distinct uptick in global regional-based tech hubs taking advantage of Digital RESI to expand into the new digital paradigm of global partnering conferences. The main strategy is to get the early stage companies back in the mix and secondly, to showcase the technology assets that are teeming in these dynamic regional hubs. The BioHealth Capital Region is a perfect example of deciding to take advantage of RESI and to expand their global reach.

The BioHealth Capital Region is uniquely positioned to help address Covid-19 with its biocluster serving as home to NIH and its 27 research institutes and 6,000 scientists, the FDA with its accelerated approval process, NIAID, BARDA and Dr. Anthony Fauci, all on the front line every day. In addition, many of the region’s industry leaders are developing innovative therapeutics, vaccines and diagnostic tools to fight the virus, including Emergent BioSolutions, Novavax, GSK, AstraZeneca, Qiagen and more than 30 more BioHealth companies of all sizes.

BioHealth Innovation, a Gold sponsor for this RESI Conference, has been busy assisting companies and entrepreneurs with their applications for the numerous Covid-19 grant opportunities, and working with international companies desiring to enter the U.S. market through the BioHealth Capital Region. We also are in the process of raising a $50 million BioHealth Capital Venture Fund to address the early stage funding gap in our ecosystem.

BioHealth Innovation, in cooperation with RESI, will be sponsoring 5 informative panels during Digital RESI June, with additional details will follow. We welcome all to join these sessions to hear from knowledgeable BioHealth experts, investors and entrepreneurs regarding best practices and information they can use to grow their businesses.

Hot Investor Mandate: USA-Based Investment Firm Seeks to Invest Up to $40M in Therapeutics Companies, With Strong Interests in CNS, Oncology, Immunology

21 May

An early stage investor in emerging life science technologies with offices in the USA seeks to invest in promising early-stage assets, create a company around each asset and then directly manage the startup. The firm’s investment sizes vary from $1-40 million. Investments are made at the seed stage or in Series A venture rounds; the firm prefers to be the first institutional investor. The firm has invested in assets sourced throughout the USA and has evaluated investment opportunities globally.

The firm primarily invests in therapeutics-focused opportunities. The firm is technologically agnostic and is open to any indication area, with a particular interest in CNS, digital health, oncology and immunology. The firm is interested in preclinical-stage assets and will consider investing in assets as early as the discovery stage.

The firm is open to working with both academic projects and entrepreneurs, and also deprioritized pharma assets. The firm generally does not make new investments into companies any later than the Series A stage. The firm supplies management and technical expertise to develop an asset if the company does not have a full management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China Cross Border VC Firm Looks For Global Investment Opportunities Across All Life Sciences Sectors, Invests Up to $10M

21 May

A healthcare focused venture capital firm based in China, with offices in Shanghai and Beijing, makes venture investments in early & growth stage companies and PIPE deals. The firm is flexible regarding the investment size; the firm can invest anywhere from several hundred thousand dollars up to USD 10 million or more. The firm generally invests in global companies with current investments mostly in US and China. The firm is actively seeking new investment opportunities.

The firm invests opportunistically in the life sciences. The firm is interested in biopharmaceuticals, medical devices, diagnostics, and mobile/digital health. Within therapeutics, the firm is most interested in oncology and neurology. The firm considers all molecules and biologics, including biosimilars and reformulated drugs. In terms of stage of development, the firm looks for products in early to late stages of clinical trials. The firm generally looks for devices in later stages of development or close to market.

The firm invests in both private and public companies, and has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Firm With Newly Closed Fund Invests in Date-Driven Healthcare Companies in North America

21 May

A USA-based venture capital firm with a new second fund closed in early 2020, invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe Firm Invests Up to €12M in Therapeutics Companies, Open to All Types of Modalities and Indication Areas

21 May

A firm based in Western Europe currently manages three funds, the newest of which closed in 2020 and focuses on investments in Europe-based therapeutics and medical innovation. The firm invests in Europe and North America, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: